REFERENCES
1. Group USMFLS. A comparison of tacrolimus (FK 506) and cyclosporine
for immunosuppression in liver transplantation. N Engl J Med .
1994;331(17):1110-1115.
2. Kuypers DRJ. Intra-Patient Variability of tacrolimus exposure in
solid organ transplantation: a novel marker for clinical outcome.Clin Pharmacol Ther . 2019.
3. Brunet M, van Gelder T, Asberg A, et al. Therapeutic Drug Monitoring
of Tacrolimus-Personalized Therapy: Second Consensus Report. Ther
Drug Monit . 2019;41(3):261-307.
4. Schutte-Nutgen K, Tholking G, Suwelack B, Reuter S. Tacrolimus -
Pharmacokinetic Considerations for Clinicians. Curr Drug Metab .
2018;19(4):342-350.
5. Hendijani F, Azarpira N, Kaviani M. Effect of CYP3A5*1 expression on
tacrolimus required dose after liver transplantation: A systematic
review and meta-analysis. Clin Transplant . 2018;32(8):e13306.
6. Loh PT, Lou HX, Zhao Y, Chin YM, Vathsala A. Significant impact of
gene polymorphisms on tacrolimus but not cyclosporine dosing in Asian
renal transplant recipients. Transplant Proc .
2008;40(5):1690-1695.
7. Ji E, Kim MG, Oh JM. CYP3A5 genotype-based model to predict
tacrolimus dosage in the early postoperative period after living donor
liver transplantation. Ther Clin Risk Manag . 2018;14:2119-2126.
8. Chen L, Prasad GVR. CYP3A5 polymorphisms in renal transplant
recipients: influence on tacrolimus treatment. Pharmgenomics Pers
Med . 2018;11:23-33.
9. Kim SH, Lee SD, Kim YK, Park SJ. Conversion of twice-daily to
once-daily tacrolimus is safe in stable adult living donor liver
transplant recipients. Hepatobiliary Pancreat Dis Int .
2015;14(4):374-379.
10. Kim JM, Kwon CH, Joh JW, et al. Conversion of once-daily
extended-release tacrolimus is safe in stable liver transplant
recipients: A randomized prospective study. Liver Transpl .
2016;22(2):209-216.
11. Suh SW, Lee KW, Jeong J, Kim H, Yi NJ, Suh KS. Risk Factors for the
Adverse Events after Conversion from Twice-Daily to Once-Daily
Tacrolimus in Stable Liver Transplantation Patients. J Korean Med
Sci . 2016;31(11):1711-1716.
12. Demetris AJ, Bellamy C, Hubscher SG, et al. 2016 Comprehensive
Update of the Banff Working Group on Liver Allograft Pathology:
Introduction of Antibody-Mediated Rejection. Am J Transplant .
2016;16(10):2816-2835.
13. Demetris A, Adams D, Bellamy C, et al. Update of the International
Banff Schema for Liver Allograft Rejection: working recommendations for
the histopathologic staging and reporting of chronic rejection. An
International Panel. Hepatology . 2000;31(3):792-799.
14. Iwasaki M, Yano I, Fukatsu S, et al. Pharmacokinetics and
Pharmacodynamics of Once-Daily Tacrolimus Compared With Twice-Daily
Tacrolimus in the Early Stage After Living Donor Liver Transplantation.Ther Drug Monit . 2018;40(6):675-681.
15. Fischer L, Trunecka P, Gridelli B, et al. Pharmacokinetics for
once-daily versus twice-daily tacrolimus formulations in de novo liver
transplantation: a randomized, open-label trial. Liver Transpl .
2011;17(2):167-177.
16. Beckebaum S, Iacob S, Sweid D, et al. Efficacy, safety, and
immunosuppressant adherence in stable liver transplant patients
converted from a twice-daily tacrolimus-based regimen to once-daily
tacrolimus extended-release formulation. Transpl Int .
2011;24(7):666-675.
17. Kuypers DR, Naesens M, de Jonge H, Lerut E, Verbeke K, Vanrenterghem
Y. Tacrolimus dose requirements and CYP3A5 genotype and the development
of calcineurin inhibitor-associated nephrotoxicity in renal allograft
recipients. Ther Drug Monit . 2010;32(4):394-404.
18. Genvigir FD, Salgado PC, Felipe CR, et al. Influence of the CYP3A4/5
genetic score and ABCB1 polymorphisms on tacrolimus exposure and renal
function in Brazilian kidney transplant patients. Pharmacogenet
Genomics . 2016;26(10):462-472.
19. Tremblay S, Nigro V, Weinberg J, Woodle ES, Alloway RR. A
Steady-State Head-to-Head Pharmacokinetic Comparison of All FK-506
(Tacrolimus) Formulations (ASTCOFF): An Open-Label, Prospective,
Randomized, Two-Arm, Three-Period Crossover Study. Am J
Transplant . 2017;17(2):432-442.
20. Min SI, Kim SY, Ahn SH, et al. CYP3A5 *1 allele: impacts on early
acute rejection and graft function in tacrolimus-based renal transplant
recipients. Transplantation . 2010;90(12):1394-1400.
21. Barry A, Levine M. A systematic review of the effect of CYP3A5
genotype on the apparent oral clearance of tacrolimus in renal
transplant recipients. Ther Drug Monit . 2010;32(6):708-714.
22. Mizuno S, Hamada T, Nakatani K, et al. Monitoring peripheral blood
CD4+ adenosine triphosphate activity after living donor liver
transplantation: impact of combination assays of immune function and
CYP3A5 genotype. J Hepatobiliary Pancreat Sci .
2011;18(2):226-232; discussion 232-224.
23. Woillard JB, de Winter BC, Kamar N, Marquet P, Rostaing L, Rousseau
A. Population pharmacokinetic model and Bayesian estimator for two
tacrolimus formulations–twice daily Prograf and once daily Advagraf.Br J Clin Pharmacol . 2011;71(3):391-402.
24. Andrews LM, Li Y, De Winter BCM, et al. Pharmacokinetic
considerations related to therapeutic drug monitoring of tacrolimus in
kidney transplant patients. Expert Opin Drug Metab Toxicol .
2017;13(12):1225-1236.
25. Caillard S, Moulin B, Buron F, et al. Advagraf((R)) , a once-daily
prolonged release tacrolimus formulation, in kidney transplantation:
literature review and guidelines from a panel of experts. Transpl
Int . 2016;29(8):860-869.
26. Shuker N, Cadogan M, van Gelder T, et al. Conversion from
twice-daily to once-daily tacrolimus does not reduce intrapatient
variability in tacrolimus exposure. Ther Drug Monit .
2015;37(2):262-269.
Table 1. Baseline characteristics of the study patients stratified
according to CYP3A5 expression.